Faron Pharmaceuticals Oy (LON:FARN) Shares Up 1.3% – Still a Buy?

Faron Pharmaceuticals Oy (LON:FARN) was up 1.3% on Wednesday . The stock traded as high as GBX 200 ($2.54) and last traded at GBX 195 ($2.48). Approximately 6,878 shares traded hands during mid-day trading, a decline of 85% from the average daily volume of 46,174 shares. The stock had previously closed at GBX 192.50 ($2.45).

Faron Pharmaceuticals Oy Trading Up 1.3 %

The company has a current ratio of 1.45, a quick ratio of 1.09 and a debt-to-equity ratio of 922.55. The firm has a fifty day simple moving average of GBX 184.39 and a two-hundred day simple moving average of GBX 167.85. The firm has a market cap of £204.01 million, a PE ratio of -609.38 and a beta of 0.36.

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation.